Condition: Idiopathic Hypersomnia · Sponsor: Mayo Clinic
Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.
This description comes directly from the study's public registry record.
Gabbi Montefiore · (480)574-1288 · montefiore.gabrielle@mayo.edu
Arleth Valencia · (480)342-6487 · Valencia.Arleth@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Recruiting |
| Stanford University | Redwood City, California, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05837091